Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Headache|September 10, 2019
Prognosis Following Discontinuation of OnabotulinumA Therapy in "Super-responding" Chronic Migraine PatientsJason Ching, Amanda Tinsley, John RothrockHeadache|November 4, 2010
An analysis of migraine triggers in a clinic-based populationDiane Andress-Rothrock, Wesley King, John RothrockHeadache|April 20, 2005
Botox therapy for refractory chronic migraineStafford Conway, Curtis Delplanche, Jessica Crowder, et al.Headache|July 13, 2010
Suboccipital nerve blocks for suppression of chronic migraine: safety, efficacy, and predictors of outcomeSilvia Weibelt, Diane Andress-Rothrock, Wesley King, et al.Journal of Child Neurology|September 15, 2006
Administration of intravenous tissue plasminogen activator in a pediatric patient with acute ischemic strokeMarwan I Shuayto, J Ivan Lopez, Frank GreinerHeadache|October 23, 2002
Prevalence of migraine among Mexican Americans in San Diego, California: survey 1Craig A Molgaard, John Rothrock, Paul E Stang, et al.Headache|March 16, 2007
Borderline personality disorder and migraineJohn Rothrock, Ivan Lopez, Richard Zweilfer, et al.Medgenmed : Medscape General Medicine|October 24, 2007
Two double-blind, multicenter, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity, and satisfaction outcomesStephen Landy, Sarah E DeRossett, Alan Rapoport, et al.Cephalalgia : an International Journal of Headache|April 7, 2026
Safety, tolerability, and efficacy of atogepant added to onabotulinumtoxinA for the preventive treatment of chronic migraine: A phase 3, multicenter, 24-week, open-label studyJohn Rothrock, Umer Najib, Jessica Ailani, et al.Headache|June 3, 2022
Diagnostic accuracy of an artificial intelligence online engine in migraine: A multi-center studyRobert P Cowan, Alan M Rapoport, Jim Blythe, et al.Pageof 1